Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487479 | 1.00 | ALDH1A1 (0.55) | ALDH1A1CYP2A6PTPN1ALOX5TRPA1 | |
| SCHEMBL6486311 | 0.89 | ALDH1A1 (0.62) | ALDH1A1CYP2A6ALOX5TRPA1LMNA | |
| SCHEMBL6486306 | 0.89 | ALDH1A1 (0.62) | ALDH1A1CYP2A6ALOX5TRPA1LMNA | |
| SCHEMBL25313708 | 0.85 | TTR (0.48) | ALDH1A1PTPN1ALOX5TTRPTGS1 | |
| SCHEMBL16406669 | 0.80 | ALDH1A1 (0.50) | ALDH1A1CYP2A6ALOX5TRPA1LMNA | |
| SCHEMBL646947 | 0.80 | ALDH1A1 (0.56) | ALDH1A1CYP2A6PTGS2APPMAOB | |
| SCHEMBL6185928 | 0.79 | TRPA1 (0.53) | ALDH1A1TRPA1LMNAAPPHDAC1 | |
| SCHEMBL6185924 | 0.79 | TRPA1 (0.53) | ALDH1A1TRPA1LMNAAPPHDAC1 | |
| SCHEMBL6527325 | 0.79 | ALDH1A1 (0.59) | ALDH1A1CYP2A6PTPN1ALOX5TRPA1 | |
| SCHEMBL6527327 | 0.79 | ALDH1A1 (0.59) | ALDH1A1CYP2A6PTPN1ALOX5TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867218-B2 | Compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2005-03-15 | — | — | US | disclosed |
| US-20030195200-A1 | Compounds, their preparation and use | VTVX HOLDINGS II LLC | 2003-10-16 | — | — | US | disclosed |
| US-6555577-B1 | For treatment and/or prevention of conditions mediated by the Peroxisome Proliferator-Activated Receptors (PPAR), such as diabetes and/or obesity; 3-(4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl)-2-butoxy-propionic acid for example | NOVO NORDISK A/S (DE) | 2003-04-29 | — | — | US | disclosed |
| EP-1254101-A1 | PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | Novo Nordisk A/S (DK) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055085-A1 | PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | NOVO NORDISK A/S (DK) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195200-A1 | Compounds, their preparation and use | PPARG, PPARA, PPARD | ALDH1A1 257/4885CYP2A6 190/4885PTPN1 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.